Bank of New York Mellon
ARGS

Bank of New York Mellon’s Argos Therapeutics, Inc. ARGS Stock Holding History

Bank of New York Mellon’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,203
Closed -$4K – 4515
2017
Q4 		$4K Sell
1,203
-2,516
-68% -$8.44K ﹤0.01% 4350
2017
Q3 		$13K Buy
3,719
+2,448
+193% +$11.7K ﹤0.01% 4234
2017
Q2 		$9K Sell
1,271
-1,248
-50% -$10.6K ﹤0.01% 4272
2017
Q1 		$23K Sell
2,519
-452
-15% -$28.6K ﹤0.01% 4225
2016
Q4 		$291K Sell
2,971
-1
-0% -$94 ﹤0.01% 3794
2016
Q3 		$295K Buy
2,972
+361
+14% +$37.7K ﹤0.01% 3764
2016
Q2 		$320K Buy
2,611
+1,693
+184% +$226K ﹤0.01% 3723
2016
Q1 		$117K Buy
+918
New +$74.2K ﹤0.01% 3932

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 28.91% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Bank of New York Mellon's ARGS Position: Q1 2018 in Review

Bank of New York Mellon sold out of Argos Therapeutics, Inc. (ARGS) in Q1 2018, closing a stake of 1,203 shares — an estimated $4K sold.

Bank of New York Mellon first reported a position in ARGS in Q1 2016 and held it in 8 quarters. The position peaked at $320K in Q2 2016. 16 funds tracked by Wall St. Rank hold ARGS as of Q1 2018.

  • Bank of New York Mellon reported no remaining Argos Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Bank of New York Mellon sold 1,203 Argos Therapeutics, Inc. shares in Q1 2018, an estimated $4K.
  • Bank of New York Mellon first reported a position in Argos Therapeutics, Inc. in Q1 2016 and held it in 8 quarters.
  • Bank of New York Mellon's Argos Therapeutics, Inc. position peaked at $320K in Q2 2016.
  • 16 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q1 2018.

Based on Bank of New York Mellon's 13F filing for Q1 2018, filed 15 May 2018.